Exploration into Plasma Hsa_circ_0052184 as a New Biomarker of Colorectal Cancer Prognosis

Figures & data

Figure 1 Hsa_circ_0052184 is highly expressed among CRC versus normal plasma samples. (A) Genes upregulated in the GSE172229 dataset were subjected to cluster analysis. (B) Hsa_circ_0052184 was enhanced in CRC relative to normal tissues. (C) qRT-PCR identified hsa_circ_0052184 expression in CRC samples. (D) Hsa_circ_0052184 expression in CRC cell lines and human normal colorectal cell line NCM460. (E) qRT-PCR revealed the absolute hsa_circ_0052184 RNA expression. (F) Correlation between the relative hsa_circ_0052184 RNA expression in CRC tissues and the absolute RNA expression in the plasma. *p<0.05.

Table 1 Association Between Hsa_circ_0052184 Expression and Clinicopathological Features

Variable	hsa_circ_0052184 Expression		p value
	Low	High
Age			0.524
≥60	45	52
<60	69	62
Gender			0.644
Female	53	56
Male	61	58
Tumor location			0.384
Colon	52	55
Rectum	62	59
pT status			0.295
T1–T2	38	36
T3–T4	76	78
pN status			< 0.05
N0	72	32
N1–N2	42	82
pM status			< 0.05
M0	79	29
M1	35	85
Clinical stage			< 0.05
I + II	82	22
III + IV	32	92
Tumor size (cm)			< 0.05
< 5	75	35
≥5	39	79

Table 2 Uni- (UA) and Multivariate Cox Analyses (MA) of Factors Related to the CRC Patient PFS

Characteristics	Univariate		Multivariate
	HR (95% CI)	p	HR (95% CI)	p
Age (≥60 vs <60)	0.854 (0.354–1.524)	0.352	–	–
Gender (Female vs Male)	0.674 (0.285–1.365)	0.541	–	--
Tumor location (Colon vs Rectum)	0.935 (0.524–1.468)	0.419	–	–
pT status (T1–T2 vs T3–T4)	0.452 (0.354–1.338)	0.291	–	–
pN status (N0 vs N1–N2)	1.674 (0.854–2.065)	0.035	1.854 (0.528–2.691)	0.024
pM status (M0 vs M1)	1.954 (0.595–2.224)	0.029	2.225 (0.419–2.854)	0.019
Clinical stage (I + II vs III + IV)	2.321 (1.275–3.025)	0.009	2.843 (1.425–3.516)	0.006
Tumor size (< 5 cm vs ≥5 cm)	2.165 (1.354–3.254)	0.011	2.654 (1.542–3.612)	0.008
hsa_circ_0052184 (low vs high)	2.854 (2.021–3.654)	0.006	3.251 (2.125–3.965)	0.003

Table 3 Uni- (UA) and Multivariate Cox Analyses (MA) of Factors Related to the CRC Patient OS

Characteristics	Univariate		Multivariate
	HR (95% CI)	p	HR (95% CI)	p
Age (≥60 vs <60)	0.954 (0.415–1.365)	0.464	–	–
Gender (Female vs Male)	0.754 (0.654–1.522)	0.622	–	–
Tumor location (Colon vs Rectum)	1.022 (0.652–1.658)	0.314	–	–
pT status (T1–T2 vs T3–T4)	0.714 (0.519–1.647)	0.595	–	–
pN status (N0 vs N1–N2)	1.846 (0.954–2.451)	0.031	2.012 (1.025–2.655)	0.028
pM status (M0 vs M1)	2.022 (0.699–2.519)	0.024	2.254 (0.754–2.678)	0.019
Clinical stage (I + II vs III + IV)	2.518 (1.369–3.354)	0.006	2.854 (1.254–3.521)	0.004
Tumor size (< 5 cm vs ≥5 cm)	2.254 (1.458–3.524)	0.009	2.642 (1.528–3.845)	0.005
hsa_circ_0052184 (low vs high)	3.251 (2.254–3.954)	0.003	3.425 (2.541–4.281)	0.002

Figure 2 Baseline profile and hsa_circ_0052184 content of 228 CRC patients. Elevated plasma hsa_circ_0052184 levels were linked to significantly reduced PFS (A) and OS (B) among CRC patients.

Figure 3 ROC curve analysis depicting the clinical diagnostic value of plasma hsa_circ_0052184. Circulating hsa_circ_0052184 levels provided an effective differentiation between CRC patients and healthy controls.

Figure 4 Hsa_circ_0052184 knockdown suppressed CRC cell proliferation and metastasis. (A). Hsa_circ_0052184 knockdown efficiency. (B). Influence of hsa_circ_0052184 knockdown on CRC cell proliferation, as evidenced by the CCK-8 assay. Influence of hsa_circ_0052184 knockdown on CRC cell migration (C) and invasion (D), as evidenced by the Transwell assay. *p<0.05.